MX2019013846A - Metodo. - Google Patents

Metodo.

Info

Publication number
MX2019013846A
MX2019013846A MX2019013846A MX2019013846A MX2019013846A MX 2019013846 A MX2019013846 A MX 2019013846A MX 2019013846 A MX2019013846 A MX 2019013846A MX 2019013846 A MX2019013846 A MX 2019013846A MX 2019013846 A MX2019013846 A MX 2019013846A
Authority
MX
Mexico
Prior art keywords
car
constant region
binding domains
beta constant
receptor
Prior art date
Application number
MX2019013846A
Other languages
English (en)
Inventor
MACIOCIA Paul
PULÉ Martin
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019013846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2019013846A publication Critical patent/MX2019013846A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)

Abstract

La presente invención se relaciona con un receptor antigénico quimérico (CAR) que comprende un dominio de unión a antígenos el cual se une selectivamente a la región constante del TCR beta 1 (TRBC1) o TRBC2, células, células T que comprenden el CAR, y el uso de estas células para el tratamiento de un linfoma o leucemia de células T en un sujeto.
MX2019013846A 2014-03-05 2016-08-19 Metodo. MX2019013846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method

Publications (1)

Publication Number Publication Date
MX2019013846A true MX2019013846A (es) 2020-02-24

Family

ID=52649058

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016010856A MX2016010856A (es) 2014-03-05 2015-03-05 Metodo.
MX2019013846A MX2019013846A (es) 2014-03-05 2016-08-19 Metodo.
MX2019013845A MX2019013845A (es) 2014-03-05 2016-08-19 Metodo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016010856A MX2016010856A (es) 2014-03-05 2015-03-05 Metodo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013845A MX2019013845A (es) 2014-03-05 2016-08-19 Metodo.

Country Status (23)

Country Link
US (2) US20170066827A1 (es)
EP (2) EP3125934B1 (es)
JP (5) JP6767872B2 (es)
KR (3) KR102235202B1 (es)
CN (4) CN106068276B (es)
AU (3) AU2015225944B2 (es)
BR (1) BR112016020304B1 (es)
CA (1) CA2940564C (es)
CL (4) CL2016002195A1 (es)
CU (1) CU24475B1 (es)
DK (1) DK3125934T3 (es)
ES (1) ES2758173T3 (es)
HU (1) HUE047641T2 (es)
IL (3) IL278878B (es)
MX (3) MX2016010856A (es)
MY (1) MY173567A (es)
PE (2) PE20170125A1 (es)
PH (2) PH12016501646A1 (es)
PL (1) PL3125934T3 (es)
PT (1) PT3125934T (es)
RU (3) RU2018140694A (es)
SG (3) SG10201906460PA (es)
WO (1) WO2015132598A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3868388A1 (en) * 2014-10-03 2021-08-25 Oxford University Innovation Limited Analysis of t-cell monotypia
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
TWI704158B (zh) * 2017-04-04 2020-09-11 瑞士商赫孚孟拉羅股份公司 能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
MX2020002036A (es) * 2017-08-23 2020-03-24 Dragonfly Therapeutics Inc Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
JP7372920B2 (ja) * 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
US20220144948A1 (en) * 2019-01-29 2022-05-12 Shanghai Jiao Tong University Chimeric antigen receptor and use thereof
GB2599228B (en) * 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN110317266A (zh) * 2019-07-17 2019-10-11 东北农业大学 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用
EP4121518A4 (en) * 2020-03-16 2024-06-19 Marengo Therapeutics, Inc. MANIPULATED CELL COMPOSITIONS AND METHODS OF USE THEREOF
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
JP2023523011A (ja) * 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN111537735A (zh) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 抗体检测试剂盒以及在免疫分析方面的应用
CN111549044B (zh) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 靶向trbc1 car-t细胞的制备方法与应用
EP4200401B1 (en) * 2020-08-18 2024-07-24 Medigene Immunotherapies GmbH Enrichment of t cells using an anti-cbeta antibody
KR20230074487A (ko) * 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
EP4294841A1 (en) 2021-02-17 2023-12-27 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
US20220267415A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098368T3 (es) * 1990-08-09 1997-05-01 Nat Jewish Ct Immun & Respirat Produccion de anticuerpos monoclonales contra un elemento vbeta humano de los receptores de las celulas t, utilizando vectores de adn recombinante.
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
AU2003233197A1 (en) * 2002-04-29 2003-11-17 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
JP2012501178A (ja) * 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド Ｔ細胞受容体抗体およびその使用方法
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
JP6000507B2 (ja) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 診療情報登録装置
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EA201492222A1 (ru) * 2012-05-25 2015-05-29 Селлектис Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
BR112017005245A2 (pt) * 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
US20160348073A1 (en) * 2015-03-27 2016-12-01 President And Fellows Of Harvard College Modified t cells and methods of making and using the same

Also Published As

Publication number Publication date
KR102088082B1 (ko) 2020-03-11
AU2015225944A1 (en) 2016-09-01
IL278879A (en) 2021-01-31
EP3241561A1 (en) 2017-11-08
EP3125934B1 (en) 2019-10-23
RU2016138421A3 (es) 2018-07-25
RU2744046C2 (ru) 2021-03-02
PH12020550203A1 (en) 2021-08-16
CU24475B1 (es) 2020-03-04
CA2940564C (en) 2021-06-29
CL2019001568A1 (es) 2019-08-16
KR102235202B1 (ko) 2021-04-05
PH12016501646A1 (en) 2017-02-06
SG11201606583VA (en) 2016-09-29
RU2018140694A (ru) 2018-12-10
JP2021184773A (ja) 2021-12-09
WO2015132598A1 (en) 2015-09-11
JP2024074907A (ja) 2024-05-31
CN112094353A (zh) 2020-12-18
DK3125934T3 (da) 2020-02-03
US20170066827A1 (en) 2017-03-09
HUE047641T2 (hu) 2020-05-28
CN118852462A (zh) 2024-10-29
AU2019204921A1 (en) 2019-08-01
NZ761844A (en) 2021-06-25
IL278878A (en) 2021-01-31
AU2015225944B2 (en) 2019-07-11
MY173567A (en) 2020-02-04
SG10201906461SA (en) 2019-09-27
PE20170125A1 (es) 2017-03-16
IL247110A0 (en) 2016-09-29
ES2758173T3 (es) 2020-05-04
KR20200027576A (ko) 2020-03-12
AU2019204921C1 (en) 2021-05-13
CL2019001567A1 (es) 2019-08-16
PE20211887A1 (es) 2021-09-22
JP6767931B2 (ja) 2020-10-14
MX2019013845A (es) 2020-02-24
BR112016020304B1 (pt) 2024-02-27
JP6767872B2 (ja) 2020-10-14
CN106068276B (zh) 2020-09-18
SG10201906460PA (en) 2019-09-27
CN112094347A (zh) 2020-12-18
CL2018003096A1 (es) 2019-01-11
CA2940564A1 (en) 2015-09-11
CL2016002195A1 (es) 2017-05-19
NZ761848A (en) 2021-06-25
JP2017143838A (ja) 2017-08-24
AU2019204925B2 (en) 2021-02-18
JP2017510257A (ja) 2017-04-13
MX2016010856A (es) 2017-04-13
IL278878B (en) 2022-07-01
AU2019204921B2 (en) 2021-02-18
EP3125934A1 (en) 2017-02-08
RU2021101502A (ru) 2021-06-25
AU2019204925A1 (en) 2019-08-01
PT3125934T (pt) 2019-12-16
KR20200027577A (ko) 2020-03-12
JP2020099356A (ja) 2020-07-02
CN106068276A (zh) 2016-11-02
KR102235201B1 (ko) 2021-04-05
JP7149304B2 (ja) 2022-10-06
PL3125934T3 (pl) 2020-04-30
NZ723307A (en) 2021-06-25
KR20160127130A (ko) 2016-11-02
US20170334998A1 (en) 2017-11-23
RU2016138421A (ru) 2018-04-05
BR112016020304A2 (pt) 2017-10-17

Similar Documents

Publication Publication Date Title
PH12020550203A1 (en) Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
ZA202206078B (en) Anti-cd3 antibodies and methods of use
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
MX2022003995A (es) Antigeno quimerico y receptores de celulas t y metodos de uso.
ZA201900857B (en) Anti-tigit antibodies and methods of use
MX2023001226A (es) Anticuerpos anti-lag-3.
MX2017003640A (es) Receptores antigenicos quimericos.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
IL247320A0 (en) Use of selective il-2r beta agonists in combination with antibodies against ctla-4 or pd-1 for cancer treatment
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2015013194A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado.
EP3511422A3 (en) Methods and compositions for diagnosing, prognosing, and treating endometriosis
NZ768427A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
MY192384A (en) Anti-cd3 antibodies and methods of use

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: AUTOLUS LIMITED